By Baylor College of Medicine –
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central nervous system (CNS) tumors, aggressive brain cancers with poor prognoses. A type of immunotherapy using T cells modified with chimeric antigen receptors (CAR T) has demonstrated efficacy in other cancers, but use in DMG and other CNS tumors has been limited.
